Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
, 97 (41), e12657

Infliximab Versus Cyclosporine for Severe Ulcerative Colitis Refractory to Steroids: A Protocol for Systematic Review and Meta-Analysis

Affiliations
Meta-Analysis

Infliximab Versus Cyclosporine for Severe Ulcerative Colitis Refractory to Steroids: A Protocol for Systematic Review and Meta-Analysis

Dongjie Wu et al. Medicine (Baltimore).

Abstract

Background: Infliximab and cyclosporine are two main therapies in treating acute severe ulcerative colitis (ASUC), our objective is to assess the effectiveness and safety of cyclosporine (CSA) versus infliximab (IFX) as rescue agents in patients with steroid-refractory ulcerative colitis (UC).

Methods: We will search three databases from inception to May 2018, and 19 studies are identified that infliximab and cyclosporine as a treatment in steroid-refractory UC patients. The primary outcome was short-term response to treatment. Secondary outcomes included the rates of colectomy at 3 months, 12 months, 36 months, adverse drug reactions and mortality in those who received rescue therapy.

Results: This update review will provide a high quality synthesis of current evidence of two treatment for steroid-refractory ulcerative colitis. The definition of severe colitis is according to Truelove and Witts' criteria.

Conclusions: In the treatment of steroid-resistant ulcerative colitis with infliximab and cyclosporine, there is no difference between the two treatments on short-term and long-term results.

Conflict of interest statement

The authors have no funding and no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of selection process.

Similar articles

See all similar articles

References

    1. Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of non-hospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2016;148:1035.e1033–58.e1033. - PubMed
    1. Biancone L, Michetti P, Travis S, et al. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohn's Colitis 2008;2:63–92. - PubMed
    1. Nguyen GC, Tuskey A, Dassopoulos T, et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Diseases 2010;13:1529–35. - PubMed
    1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2016;142:46.e42–54.e42. - PubMed
    1. Rocchi A, Benchimol EI, Bernstein CN, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol 2016;26:811–7. - PMC - PubMed

Publication types

MeSH terms

Feedback